Cybin Stock (NASDAQ:HELP)

Financials Chart Transcripts

Previous Close

$4.34

52W Range

$4.15 - $9.83

50D Avg

$5.06

200D Avg

$6.28

Market Cap

$229.51M

Avg Vol (3M)

$1.19M

Beta

0.81

Div Yield

-

HELP Company Profile

Clinical-stage biopharmaceutical company developing psychedelic-based therapeutics including CYB003 (deuterated psilocybin analog) for major depressive disorder and CYB004 (deuterated DMT) for generalized anxiety disorder

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

CA

Employees

50

IPO Date

Sep 13, 2019

Website

HELP Performance

HELP Financial Summary

	Mar 25	Mar 24	Mar 23
Revenue	-	-	-
Operating Income	$-143.15M	$-78.84M	$-51.52M
Net Income	$-113.14M	$-78.08M	$-40.04M
EBITDA	$-142.67M	$-78.58M	$-51.28M
Basic EPS	$-0.61	$-9.50	$-0.22
Diluted EPS	$-0.61	$-9.41	$-0.22

Fiscal year ends in Mar 25 | Currency in USD

Latest Earnings Call Transcripts

Q2 26Nov 13, 25 | 8:00 AM

Q3 22Feb 10, 22 | 8:30 AM

Q2 22Nov 15, 21 | 4:30 PM